1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

 
• By Mandy Jackson

Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries. 

Pulmonology vector illustration
Amgen continues to explore monotherapy, combinations and biomarkers for sotorasib in lung cancer • Source: Shutterstock

Amgen, Inc.’s KRAS G12C inhibitor sotorasib is showing similar benefit in Phase II in third-line non-small cell lung cancer (NSCLC) as was seen in Phase I, and analysts expect it will be enough to gain accelerated approval from the US Food and Drug Administration.

Amgen said the results of its Phase II CodeBreak 100 clinical trial in previously treated NSCLC were positive back in October, but didn’t report any data from the 126-patient trial until 28 January, as part of the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.